Abstract
Lymphocyte function-associated antigen-1 (LFA-1) belongs to the integrin family and plays an important role in leukocyte trafficking and in T-cell activation. Random screening of chemical libraries identified the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin as an inhibitor of the LFA-1/intercellular adhesion molecule (ICAM)-1 interaction. The effect of lovastatin on LFA-1 was found to be unrelated to the inhibition of HMG-CoA reductase and to be mediated by lovastatin binding to a novel allosteric site within LFA-1. The biological relevance of LFA-1 inhibition by statins with respect to the overall benefit of this drug class is reviewed. The implications of the statin effect on LFA-1 for future drug design and therapy are discussed.
MeSH terms
-
Adjuvants, Immunologic / metabolism
-
Adjuvants, Immunologic / pharmacology
-
Allosteric Site / drug effects*
-
Allosteric Site / physiology
-
Animals
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology
-
Cell Adhesion / drug effects*
-
Cell Adhesion / physiology
-
Chemotaxis, Leukocyte / drug effects*
-
Chemotaxis, Leukocyte / physiology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
-
Integrins / drug effects
-
Integrins / metabolism
-
Intercellular Adhesion Molecule-1 / drug effects*
-
Intercellular Adhesion Molecule-1 / metabolism
-
Lymphocyte Function-Associated Antigen-1 / drug effects*
-
Lymphocyte Function-Associated Antigen-1 / metabolism
Substances
-
Adjuvants, Immunologic
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Integrins
-
Lymphocyte Function-Associated Antigen-1
-
Intercellular Adhesion Molecule-1